Who
Renee D. Gala
President & CEO
Company insider
Files Form 4 as: President & CEO, Jazz Pharmaceuticals; Director, DexCom; Director, Gossamer Bio; SVP, Chief Financial Officer, Theravance Biopharma; Director, Corcept Therapeutics.
In numbers
- Trades disclosed
- 85
- Buys
- 4
- Sells
- 7
- Bought
- $277K
- Sold
- $4.1M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 3 Jun 2014
- Last trade
- 6 Oct 2026
- Last filed
- 7 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Oct 2026filed 7 Oct 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $473K2,000 at $236.40 | filing |
| 8 Sep 2026filed 10 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $485K1,967 at $246.81 | filing |
| 8 Sep 2026filed 10 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $486K2,000 at $243.03 | filing |
| 8 Sep 2026filed 10 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $485K1,967 at $246.81 | filing |
| 8 Sep 2026filed 10 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $486K2,000 at $243.03 | filing |
| 30 Jun 2026filed 2 Jul 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $1.1M4,835 at $237.72 | filing |
| 30 Jun 2026filed 2 Jul 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $1.1M4,835 at $237.72 | filing |
| 3 Jun 2026filed 5 Jun 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code G | —600 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code G | —600 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | DXCM DexComMedical Devices | SEC FORM 4 Code A | —5,605 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | DXCM DexComMedical Devices | SEC FORM 4 Code A | —5,605 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $1.3M7,065 at $188.69 | filing |
| 5 Mar 2026filed 9 Mar 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $1.3M7,065 at $188.69 | filing |
| 26 Feb 2026filed 2 Mar 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —44,465 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —44,465 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —12,741 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $919K5,371 at $171.16 | filing |
| 16 Jan 2026filed 21 Jan 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —12,741 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $919K5,371 at $171.16 | filing |
| 5 Dec 2025filed 9 Dec 2025 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $13K80 at $166.91 | filing |
News
Jazz Pharmaceuticals Reports Positive Phase 3 Results For Ziihera CombinationJAZZ · finanzen.ch · 23 Oct 2026Jazz Pharmaceuticals gets Cramer's vote of confidenceJAZZ · aol.com · 14 Oct 2026
0 headlines in the last 90 days name Renee D. Gala; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.